On this episode of Stock Movers, we take a look at some of the week's biggest gainers and decliners:

- Meta Platforms' (META) plans to manufacture its in-house AI chip made companies like Applied Materials, Lam Research, and KLA Corp. happy. The AI infrastructure companies' stocks rose, with Lumentum rising 12% and KLA and Lam Research advancing 4.5% and 6.3%, respectively. Meta's decision to move forward with its in-house chip could be a boon for Applied Materials, Lam Research, and KLA, which make wafer fab equipment that turns raw silicon wafers into microchips.

- Paramount Skydance Media (PSKY) shares are trending after a report that U.S. states could sue to block the company’s $110 billion acquisition of Warner Bros. Discovery. States concerned about the deal’s competitive impact could file suit as soon as next week, according to sources familiar with the matter.

- Forte Biosciences shares surge as much as 47%, most intraday since May 2025, after the biotech company said its experimental molecule FB102 showed a statistically significant benefit in vitiligo observed by week 24 after completion of 12-week treatment period.

On this episode of Stock Movers, we take a look at some of the week's biggest gainers and decliners:
- Meta Platforms' (META) plans to manufacture its in-house AI chip made companies like Applied Materials, Lam Research, and KLA Corp. happy. The AI infrastructure companies' stocks rose, with Lumentum rising 12% and KLA and Lam Research advancing 4.5% and 6.3%, respectively. Meta's decision to move forward with its in-house chip could be a boon for Applied Materials, Lam Research, and KLA, which make wafer fab equipment that turns raw silicon wafers into microchips.
- Paramount Skydance Media (PSKY) shares are trending after a report that U.S. states could sue to block the company&rsquo;s $110 billion acquisition of Warner Bros. Discovery. States concerned about the deal&rsquo;s competitive impact could file suit as soon as next week, according to sources familiar with the matter.
-&nbsp;Forte Biosciences shares surge as much as 47%, most intraday since May 2025, after the biotech company said its experimental molecule FB102 showed a statistically significant benefit in vitiligo observed by week 24 after completion of 12-week treatment period.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. 

Subscribe for analysis on the companies making news in global equity markets. Episodes are published throughout the day to track stock moves from New York, London, Frankfurt and Paris. Join us for investment news covering technology, energy, finance, health care, communications, industrials, utilities, consumer staples, materials, real estate and more.

Listen for five-minute conversations on today's biggest winners and losers in the stock market.&nbsp;
Subscribe for analysis on the companies making news in global equity markets. Episodes are published throughout the day to track stock moves from New York, London, Frankfurt and Paris. Join us for investment news covering technology, energy, finance, health care, communications, industrials, utilities, consumer staples, materials, real estate and more.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

Weekly Roundup: Meta's Big Week, Paramount Skydance Mixed, Forte Biosciences Soars

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/d1018399-9d6f-47cb-bab2-b483015d5e31/transcript